5-Iodo-2-Pyrimidinone-2′-Deoxyribose-Mediated Cytotoxicity and Radiosensitization in U87 Human Glioblastoma Xenografts

International Journal of Radiation Oncology Biology Physics

Volumn 69, Issue 4, 2007, Pages 1254-1261

  Kinsella, Timothy J ^a   Kinsella, Michael T ^a   Seo, Yuji ^a   Berk, Gregory ^b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b Hana Biosciences   (United States)

Author keywords

IPdR; Radiosensitization; U87 xenografts

Indexed keywords

GLIOMAS; IPDR; RADIOSENSITIZATION; U87 XENOGRAFTS;

CELL PROLIFERATION; DRUG THERAPY; GRAFTS; ONCOLOGY; RADIOTHERAPY; RATS; TUMORS;

CYTOTOXICITY;

5 IODO 2 PYRIMIDINONE 2' DEOXYRIBOSE; RADIOSENSITIZING AGENT; THYMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CANCER GRADING; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG DOSE INCREASE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIZATION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ANIMALS; BODY WEIGHT; BRAIN NEOPLASMS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIOBLASTOMA; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PRODRUGS; PYRIMIDINE NUCLEOSIDES; RADIATION-SENSITIZING AGENTS; RANDOM ALLOCATION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 35448944054     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.08.004     Document Type: Article

References (30)

1. American Cancer Society. Cancer facts and figures 2006 (2006), American Cancer Sociey, Atlanta, GA p. 10
2. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. [see comment]. N Engl J Med 352 (2005) 987-996
3. Kinsella T.J. An approach to the radiosensitization of human tumors. Cancer J Sci Am 2 (1996) 184-193
4. Kinsella T.J., Collins J., Rowland J., et al. Pharmacology and phase I/II study of continuous intravenous infusions of iododeoxyuridine and hyperfractionated radiotherapy in patients with glioblastoma multiforme. J Clin Oncol 6 (1988) 871-879
5. Sullivan F.J., Herscher L.L., Cook J.A., et al. National Cancer Institute (phase II) study of high-grade glioma treated with accelerated hyperfractionated radiation and iododeoxyuridine: Results in anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 30 (1994) 583-590
6. Urtasun R.C., Kinsella T.J., Farnan N., et al. Survival improvement in anaplastic astrocytoma, combining external radiation with halogenated pyrimidines: Final report of RTOG 86-12, Phase I-II study. [see comment]. Int J Radiat Oncol Biol Phys 36 (1996) 1163-1167
7. Prados M., Scott C., Rotman M., et al. A retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group (RTOG) trials for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 40 (1998) 653-659
8. Groves M.D., Maor M.H., Myers C., et al. A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine and vincristine for glioblastoma multiforme. Int J Radiat Oncol Biol Phys 45 (1999) 127-135
9. Schulz C.A., Mehta M.P., Badie B., et al. Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: A phase I clinical study. Int J Radiat Oncol Biol Phys 59 (2004) 1107-1115
10. Efange S.M., Alessi E.M., Shih H.C., et al. Synthesis and biological activities of 2-pyrimidinone nucleosides. 2. 5-Halo-2-pyrimidinone 2′-deoxyribonucleosides. J Med Chem 28 (1985) 904-910
11. Chang C.N., Doong S.L., and Cheng Y.C. Conversion of 5-iodo-2-pyrimidinone-2′-deoxyribose to 5-iodo-deoxyuridine by aldehyde oxidase. Implication in hepatotropic drug design. Biochem Pharmacol 43 (1992) 2269-2273
12. Kinsella T.J., Kunugi K.A., Vielhuber K.A., et al. An in vivo comparison of oral 5-iodo-2′-deoxyuridine and 5-iodo-2-pyrimidinone-2′-deoxyribose toxicity, pharmacokinetics, and DNA incorporation in athymic mouse tissues and the human colon cancer xenograft, HCT-116. Cancer Res 54 (1994) 2695-2700
13. Kinsella T.J., Kunugi K.A., Vielhuber K.A., et al. Preclinical evaluation of 5-iodo-2-pyrimidinone-2′-deoxyribose as a prodrug for 5-iodo-2′-deoxyuridine-mediated radiosensitization in mouse and human tissues. Clin Cancer Res 4 (1998) 99-109
14. Kinsella T.J., Vielhuber K.A., Kunugi K.A., et al. Preclinical toxicity and efficacy study of a 14-day schedule of oral 5-iodo-2-pyrimidinone-2′-deoxyribose as a prodrug for 5-iodo-2′-deoxyuridine radiosensitization in U251 human glioblastoma xenografts. Clin Cancer Res 6 (2000) 1468-1475
15. Kinsella T.J., Schupp J.E., Davis T.W., et al. Preclinical study of the systemic toxicity and pharmacokinetics of 5-iodo-2-pyrimidinone-2′-deoxyribose as a radiosensitizing prodrug in two, non-rodent animal species: Implications for phase I study design. Clin Cancer Res 6 (2000) 3670-3679
16. Seo Y., Yan T., Schupp J.E., et al. Differential radiosensitization in DNA mismatch repair-proficient and -deficient human colon cancer xenografts with 5-iodo-2-pyrimidinone-2′-deoxyribose. Clin Cancer Res 10 (2004) 7520-7528
17. Seo Y., Yan T., Schupp J.E., et al. Schedule-dependent drug effects of oral 5-iodo-2-pyrimidinone-2′-deoxyribose as an in vivo radiosensitizer in U251 human glioblastoma xenografts. Clin Cancer Res 11 (2005) 7499-7505
18. Kinsella T.J., Kinsella M.T., Hong S.W., et al. Toxicology and pharmacokinetic study of orally administered 5-iodo-2-pyrimidinone-2′-deoxyribose (IPdR) × 28 days in Fischer-344 rats: Impact on initial phase I trial design of IPdR-mediated radiosensitization. Cancer Chemother Pharmacol (2007) June 12 [Epub ahead of print]
19. Schulz C., Gaffney D., Lindstrom M., et al. Iododeoxyuridine radiosensitization of human glioblastoma cells exposed to acute and chronic gamma irradiation: Mechanistic, implications and clinical relevance. Cancer J Sci Am 1 (1995) 151-161
20. Camphausen K., Purow B., Sproull M., et al. Influence of in vivo growth on human glioma cell line gene expression: Convergent profiles under orthotopic conditions. Proc Natl Acad Sci U S A 102 (2005) 8287-8292
21. Blasberg R.G., Roelcke U., Weinreich R., et al. Imaging brain tumor proliferative activity with [124I]iododeoxyuridine. Cancer Res 60 (2000) 624-635
22. Berry S.E., Garces C., Hwang H.S., et al. The mismatch repair protein, hMLH1, mediates 5-substituted halogenated thymidine analogue cytotoxicity, DNA incorporation, and radiosensitization in human colon cancer cells. Cancer Res 59 (1999) 1840-1845
23. Berry S.E., Davis T.W., Schupp J.E., et al. Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine. Cancer Res 60 (2000) 5773-5780
24. Berry S.E., and Kinsella T.J. Targeting DNA mismatch repair for human tumor radiosensitization. Semin Radiat Oncol 11 (2001) 300-315
25. Friedman H.S., Dong Q., Scholds S., et al. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res 57 (1997) 2933-2936
26. Friedman H.S., McLendon R.E., Kerby T., et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in new diagnosed malignant glioma. J Clin Oncol 16 (1998) 3851-3857
27. Cahill D.P., Levine K.K., Betensky R.A., et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 13 (2007) 2038-2045
28. Taverna P., Liu L., Hwang H.S., et al. Methoxyamine potentiates DNA single strand breaks and double strand breaks induced by temozolomide in colon cancer cells. Mutat Res 485 (2001) 269-281
29. Taverna P., Hwang H.S., Schupp J.E., et al. Inhibition of base excision repair potentiates iododeoxyuridine-induced cytotoxicity and radiosensitization. Cancer Res 63 (2003) 838-846
30. Yan T., Seo Y., Schupp J.E., et al. Methoxyamine potentiates iododeoxyuridine-induced radiosensitization by altering cell cycle kinetics and enhancing senescence. Mol Cancer Ther 5 (2006) 893-902